Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

Hamzah Abu-Sbeih 1†, Tenglong Tang 1,2†, Yang Lu 3, Selvi Thirumurthi 1, Mehmet Altan 4, Amir A. Jazaeri 5, Ramona Dadu 6, Emmanuel Coronel 1 and Yinghong Wang 1*†

Abstract

**Background:** Immune checkpoint inhibitor (ICI)-induced pancreatic injury (ICIPI) is not well documented in the literature. We aimed to describe the clinical characteristics and outcomes of patients who developed ICIPI.

**Methods:** We reviewed the medical records of consecutive patients who had a confirmed diagnosis of ICIPI (Common Terminology Criteria for Adverse Events grade ≥ 3 lipase elevation with or without clinical symptoms) from April 2011 through April 2018.

**Results:** Among the 2,279 patients received ICI and had lipase values checked thereafter, 82 (4%) developed ICIPI. Overall, 65% of patients received inhibitors of programmed death protein-1 or its ligand. Compared with asymptomatic presentation, patients who had clinical symptoms of pancreatitis (n = 32) had higher levels of lipase (P = 0.032), more frequent imaging evidence of pancreatitis (P = 0.055), and more frequent hospitalization (P < 0.001) and received intravenous fluids (P < 0.001) and steroids more frequently (P = 0.008). Twelve patients (15%) developed long-term adverse outcomes of ICIPI; three had chronic pancreatitis, four had recurrence of ICIPI, and six had subsequent diabetes. Among 35 patients who resumed ICI therapy, four (11%) had recurrence of lipase elevation. Logistic regression revealed that smoking and hyperlipidemia were associated with increased risk for long-term adverse outcomes of ICIPI, and intravenous fluids were associated with reduced risk. Patients who resumed ICI therapy survived longer than patients who discontinued ICI therapy permanently, statistically not significant (P = 0.0559). Patients who developed long-term adverse outcomes of ICIPI survived significantly longer than those who did not (P = 0.0295). The highest proportion of patients (6/21, 29%) developed long-term adverse outcomes of ICIPI was among those without typical symptoms of pancreatitis, continued ICI therapy after ICIPI, and did not receive intravenous fluids.

**Conclusion:** ICIPI can present as typical acute pancreatitis, with risk of the development of a pseudocyst, diabetes, and chronic pancreatitis. ICI resumption after ICIPI may lead to recurrence of lipase elevation without increased risk of long-term adverse outcomes, and can increase survival duration. Intravenous fluids may prevent long-term adverse outcomes, but steroids do not appear to affect outcomes of ICIPI. Asymptomatic ICIPI presentation may lead to undertreatment of ICIPI owing to underestimation of its degree, and therefore, intravenous fluid administration could potentially could potentially be beneficial to prevent long-term adverse outcomes even in asymptomatic patients.

**Keywords:** Immunotherapy, Immune checkpoint inhibitor, Cytotoxic T-cell lymphocyte-4 (CTLA-4), Programmed death-1 and ligand-1 (PD-1/L1), Pancreatitis, Lipase elevation, Pancreatic injury, Pancreatic adverse events

* Correspondence: ywang59@mdanderson.org
† Hamzah Abu-Sbeih and Tenglong Tang contributed equally to this work.
1 Departments of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Full list of author information is available at the end of the article

© The Author(s). 2019. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Immune checkpoint inhibitors (ICIs), including cytotoxic T-cell lymphocyte-4 (CTLA-4) and programmed death-1 (PD-1)/ligand-1 (PD-L1) inhibitors, are effective in the treatment of a rapidly increasing number of advanced cancer types, including malignant melanoma, non-small cell lung cancer, head and neck cancers, and genitourinary and hematologic malignancies [1–9]. Currently, in the United States, 600,000 patients could benefit from ICI therapy and the number is expected to increase [10]. The overall survival rate of patients with advanced cancers has improved significantly during the past decade as a consequence of these ICI agents [11–13].

Nonetheless, ICI therapy has some drawbacks, in particular, immune-related adverse events (irAEs). IrAEs can affect almost any organ system and range from mild self-limiting symptoms to severe life-threatening events. The most commonly affected organ systems are dermatologic, gastrointestinal, hepatic, pulmonary, and endocrine systems. [14] The evaluation and management of these common irAEs have been studied extensively, and favorable cancer treatment outcomes have been reported in some cases [15–19]. Lipase elevation is an uncommon irAE, with limited information available in published studies [20–24]. One of the obstacles confronting the investigation of ICI-induced pancreatic injury (ICIPI), in addition to the very small number of patients owing to rare occurrence, is the involvement of various factors as potential causes for the elevated serum lipase. Therefore, published evidence regarding the incidence and clinical characteristics of irAEs affecting the pancreas (i.e., ICIPI) is sparse.

The resemblance between ICIPI and traditional acute pancreatitis that presents with clinical symptoms, in addition to elevated serum lipase and imaging abnormalities, has not yet been studied. ICIPI is usually asymptomatic with normal imaging findings of the pancreas, and the elevated serum lipase is detected incidentally [25]. Moreover, the clinical and imaging presentation of ICIPI is non-specific and can be attributed to several causes. Thus, current guidelines for the management of ICIPI are based on scant evidence [26–28]. Furthermore, there is no clear evidence on the impact of ICI therapy discontinuation or continuation on the pancreas after the occurrence of ICIPI.

Hence, in this retrospective case series, we aimed to describe the clinical characteristics, treatment, and outcomes of patients who developed ICIPI at a tertiary cancer center.

Materials and methods
Study design and population
We conducted a retrospective, descriptive study of adult patients who received ICI therapy at The University of Texas MD Anderson Cancer Center and developed grade ≥3 elevation of the serum lipase according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03 from April 2011 through April 2018. Grade 3 is defined as lipase elevation of >2 times the upper limit of normal (60 U/L in our laboratory). The study was approved by the Institutional Review Board at MD Anderson. Included patients met all of the following criteria: (1) aged 18 years or older, (2) received ICI therapy, and (3) developed grade ≥3 elevation of serum lipase during or after ICI therapy within 6 months. After a comprehensive medical chart review, we excluded patients who developed acute pancreatitis due to other reasons, such as endoscopic retrograde cholangiopancreatography, gallstone or biliary obstruction, alcohol, and other non-ICI drugs that have known risk of pancreatic toxicity.

Clinical data
Collected data consisted of patient demographics, comorbidities, oncology history, ICI regimen, and non-pancreatic irAEs. Patient demographics consisted of age, sex, and race/ethnicity. Smoking history, alcohol consumption, type II diabetes mellitus, drug allergy, prior history of pancreatitis, and pancreatic metastasis were considered and recorded as baseline risk factors for pancreatic injury. Comorbidities included hypertension, diabetes mellitus, hyperlipidemia, congestive heart failure, and myocardial infarction. Baseline laboratory tests were reported for all patients before ICI therapy.

Oncologic data
Oncologic details related to the type, site, and stage of cancer, as well as interruption of ICI therapy, were recorded. Malignancies were categorized as melanoma, solid tumors (including genitourinary, lung, gastrointestinal, head and neck, and other solid tumors), and hematologic malignancies. The stage of melanoma and solid tumors was assessed according to the American Joint Committee on Cancer Staging System 7th edition [29]. The stage of hematologic malignancies was not reported. ICI agents used were ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, and tremelimumab. ICI agents were categorized as (1) CTLA-4 monotherapy, (2) PD-1/L1 monotherapy, or (3) combination of both. The mean duration of ICI therapy and the median number of ICI doses were recorded. Reasons for ICI therapy discontinuation, permanent or temporary, were also documented.

Pancreas-related data
Baseline lipase and amylase values were assessed for all patients to check for pancreatic injury prior to ICI therapy. We collected the peak value of serum lipase and amylase, as well as computed tomography (CT) findings.
of the pancreas (such as peripancreatic fat stranding, pancreatic enlargement with heterogeneous enhancement, and segmental hypoenhancement). We defined ICIPI as elevation of lipase with and without clinical presentation. Typical clinical presentation of acute pancreatitis was epigastric pain aggravated by leaning forward or radiating to the back, with or without associated nausea and vomiting. Other clinical signs and symptoms of ICIPI included fever, diarrhea, dyspnea, and hemodynamic instability (as a result of ICIPI or other reasons). Diarrhea was recorded as a part of ICIPI clinical presentation if it was not diagnosed previously as a symptom of immune-mediated colitis and was not of infectious cause. Thereafter, patients were divided into two groups on the basis of the presence of typical acute pancreatitis symptoms. Duration of clinical symptoms was measured from symptom onset to improvement.

Data relating to the treatment of pancreatic injury included use and amount of intravenous (IV) fluid, corticosteroids (either for pancreatitis only or concurrently for other reasons), and duration of treatment. Hospitalization to treat elevated serum lipase with IV fluids or/and steroids was also documented. Short-term adverse outcomes of ICIPI were reported as pancreatic pseudocyst and need for hospitalization (along with duration of hospitalization). Long-term adverse outcomes of pancreatitis included diabetes, chronic pancreatitis features on imaging (such as pancreatic atrophy), and recurrence of lipase elevation within a mean follow-up duration of 16 months.

Statistical analysis
The distribution of continuous variables was summarized by means and standard deviations or medians and interquartile ranges. The distribution of categorical variables was summarized using frequencies and percentages. Continuous variables were compared between groups using the Wilcoxon rank-sum test. The Fisher exact test was conducted to evaluate associations between categorical variables. Univariate logistic regression analysis was conducted to assess for the risk of long-term adverse outcomes of ICIPI. Kaplan-Meier curves and the log-rank test were used to estimate and compare unadjusted overall survival time distributions. A multivariable Cox proportional hazards model was used to evaluate the ability of independent covariates to predict overall survival. All statistical evaluations were two-sided, and a P value of ≤0.05 was considered statistically significant. Statistical analysis was carried out using the SPSS Statistics software program (version 24.0; IBM Corporation, Armonk, NY).

Results
Patient characteristics
Among 5,762 patients who received ICI therapy during the period studied, 2,279 patients had lipase levels tested; 627 patients received anti-CTLA-4 monotherapy, 1,434 received PD-1/L1 monotherapy, and 218 received combination therapy. In the CTLA-4 monotherapy group, 12 patients (2%) developed grade ≥ 3 serum lipase elevation that was deemed related to ICI therapy. Among patients who received PD-1/L1 monotherapy, 53 (4%) had ICIPI. In the combination therapy group, 17 (8%) developed ICIPI. Thus, our cohort included 82 patients. Baseline clinical characteristics of the patients are shown in Table 1. In our cohort, most patients (66%) were male with a mean age of 57 years. Melanoma was the most common malignancy in our cohort (37%). The median number of ICI doses was 4 (interquartile range 1–25). Other non-pancreatic irAEs reported at the time of ICIPI onset included enterocolitis in 27 patients (33%), hepatic injury in 17 patients (21%), dermatologic events in 13 patients (16%), and endocrine events in 7 patients (9%).

Clinical characteristics of ICIPI
The median time from ICI initiation to peak lipase elevation was longer in patients who received PD-1/L1 monotherapy than in patients who received CTLA-4–based regimens (median 146 days for PD-1/L1 compared with 69 days for CTLA-4 monotherapy and 110 days for combination therapy, P = 0.033; Additional file 1: Table S1). Clinical symptoms of pancreatitis were epigastric pain in 32 patients (39%), nausea and vomiting in 23 (28%), fever in 7 (9%), and diarrhea in 16 (20%). Twenty-four patients had more than one of these symptoms. Forty-five patients had completely asymptomatic presentation. Three of the patients who had completely asymptomatic presentation had CT findings suggestive of ICIPI with lipase elevation. No differences were observed in the clinical characteristics of patients according to ICI type. Typical pancreatitis presentation was observed in 32 patients (39%) and the other 50 (61%) did not have typical pancreatitis symptoms (Table 2). According to CTCAE grades for pancreatitis, 41 patients (50%) in our cohort had grade 2 pancreatitis (enzyme elevation or radiologic findings only) and the rest had grade 3 pancreatitis (pain, vomiting, medical intervention indicated). Fever occurred more frequently in patients with typical symptoms of pancreatitis than in those with asymptomatic lipase elevation (P = 0.013). Patients with a prior history of pancreatitis had an increased risk of ICIPI with clinical symptoms (P = 0.013). Although not statistically significant, CT findings suggestive of pancreatitis were more prevalent in patients who had symptoms of pancreatitis than in those who did not (P = 0.055). Patients with clinical symptoms of pancreatitis developed higher mean peak values of serum lipase than did patients without symptoms (3227 U/L for clinical symptoms compared with 1989 U/L for no symptoms, P = 0.032). There was no statistically significant difference in the peak values...
of serum amylase between the two groups (378 U/L for clinical symptoms compared with 270 U/L for no symptoms, \( P = 0.082 \)).

ICI therapy was more often discontinued in patients who developed clinical symptoms than in patients without symptoms of pancreatitis (\( P = 0.012 \)). Thirty-two patients received IV fluids for ICIPI; most were normal saline (\( n = 28 \)), followed by \( \frac{1}{2} \) normal saline (\( n = 3 \)) and lactated ringer (\( n = 1 \)). IV fluids were given more frequently in patients who developed clinical symptoms of pancreatitis than in patients who did not (\( P < 0.001 \)). Patients who had clinical symptoms of pancreatitis received steroids and required hospitalization more frequently than patients who had no symptoms (\( P = 0.008 \) for steroid; \( P < 0.001 \) for hospitalization).

Eleven patients (13\%) had pancreatic metastasis at the time of ICI initiation. Mean baseline lipase values were similar between patients who had pancreatic metastasis and those who did not (146 for those with metastasis and 162 for those with no metastasis, \( P = 0.769 \)). We did not find any statistically significant differences in regards to epigastric pain (\( P = 0.325 \)) and peak lipase value (\( P = 0.827 \)) between patients who had pancreatic metastasis and those who did not. Also, there was no statistically significant difference in the prevalence of CT findings of pancreatitis (\( P = 0.238 \)) and the treatment administered for pancreatitis (IV fluid, \( P = 0.325 \); steroids, \( P = 0.347 \)) between patients who had pancreatic metastasis and those who did not. No significant associations were found between pancreatic metastasis and short-term or long-term adverse outcomes of ICIPI.

**Radiologic characteristics of pancreatic injury**

Among the 64 patients who had CT scan evaluation, findings of pancreatitis were found in 11 patients (17\%). The most common features suggestive of pancreatitis were segmental hypoenhancement, stranding in peripancreatic fat, and pancreatic enlargement with heterogeneous enhancement. Three of the patients who had CT findings of pancreatitis had also pancreatic metastasis, and the other eight did not. Additional file 2: Figure S1 shows features of pancreatitis with and without pancreatic metastasis.

**Short-term outcomes of ICIPI**

In regards to short-term clinical outcomes of ICIPI, three patients (4\%) developed a pancreatic pseudocyst and 18 (22\%) required hospitalization with a mean duration of 5 days. The associations of steroids and IV fluids with short-term outcomes of ICIPI are summarized in Table 3. The use of steroids and IV fluids did not shorten the time from peak lipase value to improvement to grade 1 or below (\( P = 0.711 \) for steroids and \( P = 0.850 \) for IV fluids), the duration of symptoms (\( P = 0.824 \) for

**Table 1** Clinical characteristics of patients in our cohort (\( n = 82 \))

| Characteristic                                      | No. of patients (%) |
|----------------------------------------------------|---------------------|
| Mean age (standard deviation)                       | 57 years (14)       |
| Male sex                                           | 54 (66)             |
| Race/ethnicity                                     |                     |
| White                                              | 63 (77)             |
| Black                                              | 7 (9)               |
| Hispanic                                           | 9 (11)              |
| Other                                              | 3 (4)               |
| Baseline risk factors                              |                     |
| History of smoking                                 | 35 (43)             |
| Alcohol consumption                                | 35 (43)             |
| Type II diabetes mellitus                          | 21 (26)             |
| Drug allergy                                       | 51 (62)             |
| Prior history of pancreatitis                      | 7 (9)               |
| Pancreatic metastasis                              | 11 (13)             |
| Cancer type                                        |                     |
| Melanoma                                           | 30 (37)             |
| Genitourinary                                      | 24 (29)             |
| Lung, head and neck                                | 11 (13)             |
| Gastrointestinal                                   | 5 (6)               |
| Other solid tumors                                 | 5 (6)               |
| Hematologic malignancies                           | 7 (9)               |
| Cancer stage\(^a\)                                 |                     |
| Stage III                                          | 3 (4)               |
| Stage IV                                           | 72 (96)             |
| Median number of immune checkpoint inhibitor doses (interquartile range) | 4 (1-25) |
| Checkpoint inhibitor type                          |                     |
| CTLA-4 monotherapy                                 | 12 (15)             |
| PD-1/L1 monotherapy                                | 53 (65)             |
| Combination therapy\(^b\)                          | 17 (21)             |
| Other immune-related adverse events                |                     |
| Gastrointestinal                                   | 27 (33)             |
| Hepatic                                            | 17 (21)             |
| Dermatologic                                       | 13 (16)             |
| Endocrine                                          | 7 (9)               |
| Pulmonary                                          | 5 (6)               |
| Other                                              | 6 (7)               |

\(^{a}\)Cancer stage was recorded for 75 patients. For solid tumors, the TNM system of the American Joint Committee on Cancer 7th edition was used for cancer staging. No cancer stage was recorded for hematologic cancer.

\(^{b}\)Combination of CTLA-4 and PD-1 or PD-L1 therapy.
steroids and \( P = 0.650 \) for IV fluids), or the duration of hospitalization (\( P = 0.762 \) for steroids and \( P = 0.166 \) for IV fluids). The administration of steroids or IV fluids was not associated with ICI therapy discontinuation (\( P = 1.000 \) for steroids and \( P = 0.113 \) for IV fluids). Upon stratifying patients by the grade of lipase elevation, we found that steroid therapy did not affect the short-term outcomes in patients with grade 3 compared with grade 4 lipase elevation (Additional file 1: Table S2). Similarly, IV fluid administration was not associated with different short-term outcomes in patients with grade 3 or grade 4 lipase elevation (Additional file 1: Table S3).

### Long-term adverse outcomes of ICIPI

Long-term adverse outcomes of ICIPI were chronic pancreatitis in three patients (4%) and diabetes in six (7%); five of them required insulin and the sixth required metformin. Four of the patients who developed consequent diabetes did not receive steroids for ICIPI. Additionally, 4 of the 35 patients (11%) who resumed ICI therapy after ICIPI had recurrence of lipase elevation, one symptomatic and three asymptomatic. Patients who developed adverse outcomes of ICIPI received longer-duration ICI therapy than patients who did not (mean 412 days for adverse outcomes and 200 days for no adverse outcomes, \( P = 0.006 \);

---

**Table 2 Clinical characteristics and outcomes stratified by clinical symptoms**

| Characteristic | Typical pancreatitis symptoms, \( n = 32 \) | No typical pancreatitis symptoms, \( n = 50 \) | \( P \) |
|---------------|---------------------------------------------|---------------------------------------------|-----|
| Median time from immune checkpoint inhibitor initiation to peak lipase value (interquartile range) | 107 days (3-511) | 116 days (8-699) | 0.520 |
| Baseline risk factors | | | |
| History of smoking | 14 (44) | 21 (42) | 1.000 |
| Alcohol consumption | 12 (38) | 23 (46) | 0.498 |
| Type II diabetes mellitus | 6 (19) | 15 (30) | 0.307 |
| Drug allergy | 22 (69) | 29 (58) | 0.360 |
| Prior history of pancreatitis | 6 (19) | 1 (2) | 0.013 |
| Pancreatic metastasis | 6 (19) | 5 (10) | 0.325 |
| Mean biochemistry peak value (standard deviation) | | | |
| Lipase | 3227 U/L (3563) | 1989 U/L (1479) | 0.032 |
| Amylase | 378 U/L (335) | 270 U/L (217) | 0.082 |
| Computed tomography findings of pancreatitis | 8 (25) | 3 (6) | 0.055 |
| Hemodynamic instability | | | |
| Pancreatitis only | 5 (16) | 2 (4) | 0.214 |
| Other reasons | 6 (19) | 12 (24) | |
| Fever | 6 (19) | 1 (2) | 0.013 |
| Immune checkpoint inhibitor therapy discontinued | 24 (75) | 23 (46) | 0.012 |
| Treatment for pancreatitis | | | |
| Intravenous fluids | 23 (72) | 9 (18) | <0.001 |
| Fluid amount* | 3.9 L (1.4 L) | 3.9 L (3.1 L) | 0.995 |
| Steroids | | | |
| For pancreatitis only | 9 (28) | 2 (4) | |
| For other reasons also | 5 (16) | 15 (30) | |
| Mean time from peak lipase value to improvement to grade 1 (standard deviation) | 55 days (54) | 53 days (48) | 0.877 |
| Outcomes** | | | |
| Pancreatic pseudocyst | 2 (6) | 9 (18) | 0.188 |
| Hospitalization | 2 (6) | 1 (2) | 0.557 |
| Diabetes | 15 (47) | 0 (0) | <0.001 |
| Chronic pancreatitis features | 1 (3) | 2 (4) | 1.000 |
| Recurrence | 1 (3) | 3 (6) | 1.000 |

*The amount of intravenous fluid administered within 48 hours after the onset of immune checkpoint inhibitor-induced pancreatic injury was recorded.
**Including short-term outcomes (pancreatic pseudocyst and hospitalization) and long-term outcomes (diabetes, chronic pancreatitis features, and recurrence)
IV fluids were more frequently given to patients without subsequent long-term adverse outcomes of ICIPI than patients with adverse outcomes ($P = 0.044$). Results of logistic regression analysis of long-term adverse outcomes are shown in Table 5. Smoking history (odds ratio 4.35; 95% confidence interval 1.06–17.81, $P = 0.041$) and hyperlipidemia (odd ratio 6.15; 95% confidence interval 1.24–30.55, $P = 0.026$) were associated with an increased risk of long-term adverse outcomes of ICIPI. Patients who received IV fluids had a favorable ICIPI long-term outcomes profile (odds ratio 0.21; 95% confidence interval 0.06–0.79, $P = 0.022$).

### Table 3: Short-term clinical outcomes of pancreatitis by treatment for immune checkpoint inhibitor-induced pancreatic injury

| Outcome                                      | Steroids, no. (%) | No steroids, n = 51 | P       | Intravenous fluids, no. (%) | No intravenous fluids, n = 50 | P       |
|-----------------------------------------------|-------------------|---------------------|---------|-----------------------------|-------------------------------|---------|
| Mean time from peak lipase value to improvement to grade 1 (standard deviation) | 55 days (11)       | 48 days (7)         | 0.711   | 55 days (51)                | 52 days (49)                  | 0.850   |
| Mean duration of symptoms (standard deviation) | 5 days (3)         | 4 days (2)          | 0.824   | 4 days (3)                  | 5 days (3)                    | 0.650   |
| Pseudocyst                                    | 1 (3)             | 2 (4)               | 1.000   | 6 (19)                      | 9 (18)                        | 0.056   |
| Hospitalization                               | 6 (19)            | 9 (18)              | 1.000   | 6 (19)                      | 9 (18)                        | <0.001  |
| Mean duration of hospitalization (standard deviation) | 4 days (3)        | 5 days (2)          | 0.762   | 5 days (3)                  | 1 day (-)                     | 0.166   |
| Intravenous fluids                            | 14 (45)           | 18 (35)             | 0.484   | 14 (44)                     | 17 (34)                       | 0.484   |
| Steroids                                      | -                 | -                   | -       | -                           | -                             | -       |
| Immune checkpoint inhibitor therapy interrupted| 18 (58)           | 29 (57)             | 1.000   | 22 (69)                     | 25 (50)                       | 0.113   |

*Improvement was defined as return of lipase value to grade 1.

### Table 4: Clinical characteristics of patients who had adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury (chronic pancreatitis, diabetes, and recurrence)

| Characteristic                                      | No. (%) | P       |
|-----------------------------------------------------|---------|---------|
| Mean duration of ICI therapy (standard deviation)   | 412 days (361) | 200 days (197) | 0.006 |
| Checkpoint inhibitor type                           |         | 0.739   |
| CTLA-4–based therapy                               | 3 (27)  | 26 (37) |         |
| PD-1/L1 monotherapy                                | 8 (73)  | 45 (63) |         |
| Clinical presentation                               |         |         |
| Epigastric pain                                     | 2 (18)  | 30 (42) | 0.188  |
| Nausea and vomiting                                 | 2 (18)  | 21 (30) | 0.720  |
| Fever                                               | 1 (9)   | 6 (8)   | 1.000  |
| Dyspnea                                            | 0 (0)   | 17 (24) | 0.109  |
| Hemodynamic instability                             | 1 (9)   | 24 (34) | 0.159  |
| Mean peak lipase value (standard deviation)         | 1700 U/L (636) | 2592 U/L (2723) | 0.285 |
| Computed tomography findings of pancreatitis       | 1 (9)   | 10 (14) | 1.000  |
| Mean duration from peak lipase value to improvement to grade 1 (standard deviation) | 59 days (33) | 53 days (53) | 0.693 |
| Immune checkpoint inhibitor therapy resumption      | 7 (64)  | 28 (39) | 0.191  |
| Treatment for pancreatitis treatment                |         |         |
| Hospitalization                                     | 1 (9)   | 14 (20) | 0.679  |
| Intravenous fluids                                  | 1 (9)   | 31 (44) | 0.044  |
| Fluid amount                                       | 2.1 L (-) | 3.9 L (2.0) | 0.382  |
| Steroids                                            | 5 (45)  | 26 (37) | 0.740  |

*CTLA-4–based therapy included CTLA-4 monotherapy and combination of CTLA-4 and PD-1/L1 agents.

*Improvement was defined as return of lipase value to grade 1.

*The amount of intravenous fluid administered within 48 hours after the onset of immune checkpoint inhibitor-induced pancreatic injury.

*Only one patient had data available.
No significant associations were reported between long-term adverse outcomes of ICIPI and ICI type, symptoms of pancreatitis, abnormal CT findings, peak lipase and amylase values, and use of steroids.

Among the 82 patients, 18 received IV fluids without steroids, and none of these patients developed long-term adverse outcomes from ICIPI. Fourteen patients received both IV fluids and steroids, and among these patients, only one (7%) developed long-term adverse outcomes of ICIPI. On the other hand, four of the 17 patients (24%) who received steroids without IV fluids developed long-term adverse outcomes from ICIPI. Similarly, six of the 33 patients (18%) who received neither IV fluids nor steroids developed long-term adverse outcomes (Additional file 3: Figure S2A).

Only one (3%) of the 32 patients who received IV fluids developed long-term adverse outcomes of ICIPI, whereas 10 (20%) of the 50 patients who did not receive IV fluids had long-term adverse outcomes. None of the patients who discontinued ICI therapy after ICIPI and received IV fluids had long-term adverse outcomes (Fig. 1). By contrast, 24% of the patients who continued ICI therapy and did not receive IV fluids had long-term adverse outcomes. Overall, patients who had no symptoms of pancreatitis and received no IV fluids had the highest rate of long-term adverse outcomes of ICIPI (22%) among all patients (Fig. 2). A total of 21 patients had no typical symptoms of pancreatitis, continued ICI therapy after ICIPI, and did not receive IV fluids. Of these, 6 (29%) had long-term adverse outcomes. Long-term outcomes of ICIPI stratified by the duration of follow-up is shown in Additional file 4: Figure S2B.

### ICIPI and overall survival

Kaplan-Meier curves showed that patients who resumed ICI therapy after ICIPI onset had slightly longer overall survival than did patients who did not, although this was not statistically significant ($P = 0.0559$; Additional file 5: Figure S3). Patients with long-term adverse outcomes of ICIPI had significantly longer overall survival duration than did patients without long-term adverse outcomes ($P = 0.0295$; Additional file 6: Figure S4). Overall survival rate did not differ between patients who received steroids and those who did not ($P = 0.4088$; Additional file 7: Figure S5) or between those who had symptoms of pancreatitis and those who did not ($P = 0.1436$; Additional file 8: Figure S6). The multivariable Cox model showed no significant associations between any of the clinical features and overall survival duration (Additional file 1: Table S4).

### Discussion

The current study represents by far the largest case series of patients with cancer who experienced ICIPI related to anti-CTLA-4 or anti-PD-1/L1 therapy. We found that this infrequent event can present as typical clinical symptoms of acute pancreatitis or it can be asymptomatic and present as an incidental finding. Correspondingly, ICIPI can present on CT imaging with features similar to those of traditional malignancies.
Fig. 1 Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by treatment for pancreatitis.

Fig. 2 Long-term adverse outcomes of immune checkpoint inhibitor (ICI)-initiated pancreatic injury by discontinuation of ICI therapy and use of intravenous fluids.
acute pancreatitis. In addition, ICPI can lead to long-term adverse outcomes similar to those of acute pancreatitis. We found that the administration of IV fluids within 48 h after serum lipase elevation was associated with a reduced risk of long-term adverse outcomes. In contrast, corticosteroids had no significant benefit in shortening the acute phase of ICPI, preventing long-term adverse outcomes from ICPI, or improving overall survival rates. This observation remained the same when we stratified patients by the grade of lipase elevation. Furthermore, we found that ICI resumption after ICPI led to statistically insignificant longer overall survival durations.

Although ICPI is uncommon and management procedures are generally not well defined, it is likely that the incidence of ICPI will increase with the increasing use of ICIs, and thus awareness of this potential complication should be increased. Although any organ or tissue can be affected by irAEs, the dermatologic, gastrointestinal, hepatic, pulmonary, and endocrine systems are the most commonly affected [17]. We found that ICPI was more common in patients with other adverse events. We therefore recommend that lipase values be obtained in patients who are diagnosed with non-pancreatic irAEs.

The incidence of ICPI in our cohort was 2% for anti-CTLA-4 monotherapy, 4% for anti-PD-1/L1 monotherapy, and 8% for combination therapy. Our findings corroborate those of a meta-analysis showing that the incidence of ICPI was 0.9–3% in patients receiving anti-CTLA-4 monotherapy, 1.2–2.1% in patients receiving combination therapy of anti-CTLA-4 and anti-PD-1, and 0.5–1.6% in patients receiving anti-PD-1 monotherapy [22]. Freeman-Keller et al. found that 1.35% of patients with resected and unresectable metastatic melanoma treated with nivolumab had asymptomatic grade 3 amylase/lipase elevation [30].

Clinical symptoms of pancreatitis were evident in 39% of patients with grade 3 or higher lipase elevation. The clinical presentation of ICPI was similar to the clinical picture of traditional acute pancreatitis, including epigastric pain, nausea and vomiting, fever, and diarrhea. Our findings are consistent with those of a case series of 21 patients with ICI-induced serum lipase elevation, in which 14% of patients developed symptoms of pancreatitis and 86% of patients were asymptomatic [21]. No statistically significant differences were found in that study regarding the presence of clinical symptoms in patients who received anti-CTLA-4–based therapy compared with those who received anti-PD-1/L1 therapy. However, we found that patients who received anti-PD-1/L1 therapy developed elevated serum lipase later than did patients who received anti-CTLA-4–based therapy. Our findings are consistent a previous study showing that irAEs tended to present slightly later after anti-PD-1 therapy than after anti-CTLA-4 therapy [31].

Patients with clinical symptoms of pancreatitis had higher mean peak serum lipase values than did patients without clinical symptoms. This is not the case in patients with acute pancreatitis from other causes, where the level of serum lipase doesn’t correlate with the severity of pancreatic injury. Although elevated lipase values cannot determine the severity of pancreatitis, they do indicate an increased risk of pancreatitis [32]. According to our results, abnormal CT findings were more frequently found in patients who developed ICPI with clinical symptoms than in patients without clinical symptoms. However, only 13% of our cohort had abnormal CT findings. This finding suggests that CT is not useful in the evaluation and management of ICPI.

Pancreatic tumors are rarely the cause of acute pancreatitis [32]. However, whether pancreatic metastasis is associated with ICPI and leads to acute pancreatitis is not clear. There are no data in the medical literature regarding the relationship between pancreatic metastasis and ICPI. In our cohort, we assessed the effect of pancreatic metastasis on the clinical characteristics of ICPI. Between those who had pancreatic metastasis and those who did not, we observed similar clinical presentation, mean peak value of lipase, CT findings of pancreatitis, treatment for ICPI, and adverse outcomes of ICPI.

Because of the lack of evidence and rare occurrence of ICPI, the appropriate management of such events, which might lead to long-term adverse outcomes with an associated decrease in quality of life, has not been studied. Current guidelines on the evaluation and treatment of irAEs are very limited for ICPI [27, 33]. Immunosuppressive therapy, such as steroids, is usually considered when managing irAEs [14, 17]. However, we did not find that steroids had any value in the treatment of ICPI, in terms of preventing short-term and long-term adverse outcomes or improving overall survival. In addition, steroids might counteract the antitumor effects of ICIs, which are T-lymphocyte–mediated. Although a previous study suggested that steroids may improve clinical symptoms [16], this was not observed in our study.

The most prominent finding of our case series is the usefulness of aggressive IV fluid replacement in the treatment of ICPI, which decreased the risk of long-term adverse outcomes of ICPI, especially when ICI therapy was discontinued. This is part of the standard management of traditional acute pancreatitis, along with vital signs being closely monitored for any complications caused by pancreatitis [34]. Our study showed that patients with ICPI who had clinical symptoms received IV fluids more frequently than those without clinical symptoms. This finding suggests that patients with asymptomatic ICPI could have been undertreated owing to underestimation of the degree of ICPI. This contradicts a
previous recommendation to treat asymptomatic lipase elevation as an insignificant finding [21]. Our findings indicate that IV fluid administration should be considered, even in asymptomatic patients, for lipase elevation of grade 3 or higher, especially within 48 h of onset, to minimize long-term adverse outcomes. The presence of clinical symptoms may not correlate with the severity of ICIPI, but they may trigger earlier attention and evaluation. Nonetheless, according to CTCAE 4.03, pancreatic clinical symptoms are factors of the grade of pancreatitis; grade 3 pancreatitis presents with severe pain and vomiting and medical intervention is indicated, whereas grade 4 pancreatitis presents with life-threatening consequences and urgent intervention is indicated. Further prospective large-scale studies are needed to assess the significance of clinical symptoms in the management of ICIPI.

According to our findings, the resumption of ICI therapy was not associated with increased risk of long-term adverse outcomes of ICIPI. Additionally, overall survival was slightly longer in patients who resumed ICI therapy than in those who discontinued ICI therapy permanently. This finding could be confounded by the fact that patients who did not resume ICI might have had cancer progression that precluded them from receiving ICI therapy, and therefore, they had shorter survival duration. Michot et al. suggested withholding ICIs until lipase elevation is resolved and then resuming them or changing to an alternative anticancer therapy [21]. The findings of the current study support their recommendation that temporary ICI interruption followed by resumption once lipase values improve could potentially maximize the anticancer effect of ICIs.

Although the current study is the largest case series of patients with ICIPI, the study has certain limitations, mainly owing to its retrospective nature. First, our sample size was not adequate to perform further analysis to assess associations between ICIPI clinical outcomes and clinical features. Second, ICIPI consisted of both acute pancreatitis cases as well as asymptomatic lipase elevation. The extent of pancreatic injury in the latter could not be certainly depicted, and it could lead to an overestimation of pancreatic injury. Third, because evidence on the management of ICIPI in the medical literature is sparse, and no high quality evidence-based treatment guidelines are available for ICIPI, the treatment of ICIPI in our study was mainly at the discretion of the primary oncologist and based on the general clinical condition of the patient. Last, the cause of pancreatic injury is usually complex and involves numerous factors. Therefore, although we were able to exclude most of the causes that are reported to be associated with pancreatitis, we could not confirm that every case of pancreatic injury was related to ICI therapy.

Conclusion
ICIP, as an uncommon irAE, can present as typical acute pancreatitis in a subset of patients and may lead to the development of a pseudocyst and subsequent endocrine and exocrine insufficiency. In our series, the presence of symptoms of ICIPI was not an indicator of its severity or long-term adverse outcomes and overall survival. Regarding the management of ICIPI, IV fluid administration may decrease the risk of long-term adverse outcomes. In contrast, the benefit of steroids was not observed in preventing long-term adverse outcomes of ICIPI or improving overall survival. The resumption of ICI therapy after the improvement of grade 3 or higher lipase elevation appeared to have a low risk for morbidity and could potentially lead to favorable survival outcomes.

Additional files

Additional file 1: Table S1. Patient clinical characteristics by type of immune checkpoint inhibitor therapy. Table S2. Short-term outcomes by grade of lipase elevation for patients who received steroids. Table S3. Short-term outcomes by the grade of lipase elevation for patients who received intravenous fluids. Table S4. Multivariable Cox regression for overall survival. (DOCX 16 kb)

Additional file 2: Figure S1. Computed tomography findings of ICIPI. (A) Images from a patient with pancreatic metastasis, demonstrating peripancreatic fat stranding indicating acute pancreatitis (short block arrow) and pancreatic duct dilation indicating metastasis in the pancreatic head (long arrow). (B) Images from a patient without pancreatic metastasis, demonstrating segmental hypoenhancement of the pancreatic head and proximal pancreatic body suggestive of acute pancreatitis (short block arrow), compared with normal enhancement of the distal pancreatic body and pancreatic tail (long arrow). (TIF 64274 kb)

Additional file 3: Figure S2A. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by clinical symptoms of pancreatitis and use of intravenous fluids. (TIF 2184 kb)

Additional file 4: Figure S2B. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by the median duration of follow-up and use of intravenous fluids. (TIF 2750 kb)

Additional file 5: Figure S3. Kaplan-Meier overall survival curves in patients who resumed and discontinued immune checkpoint inhibitor (ICI) therapy. (TIF 50634 kb)

Additional file 6: Figure S4. Kaplan-Meier overall survival curves in patients who did and did not have long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury. (TIF 49723 kb)

Additional file 7: Figure S5. Kaplan-Meier overall survival curves in patients who did and did not receive steroids for immune checkpoint inhibitor-induced pancreatic injury. (TIF 48223 kb)

Additional file 8: Figure S6. Kaplan-Meier overall survival curves in patients who did and did not have symptoms of pancreatitis with immune checkpoint inhibitor-induced pancreatic injury. (TIF 50469 kb)

Abbreviations
CT: Computed tomography; CTCAE: Common Terminology for Adverse Events; CTLA-4: Cytotoxic T-cell lymphocyte-4; ICI: Immune checkpoint inhibitor; ICIPI: ICI-induced pancreatic injury; irAE: Immune-related adverse event; IV: Intravenous; PD-1: Programmed death-1; PD-L1: Programmed death ligand-1
Acknowledgments
Medical editing of this paper was provided by the Department of Scientific Publications at MD Anderson Cancer Center.

Funding
This study was not supported by any funding.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
YW was the senior author of this study, developed the concept, designed the study, interpreted the results, ensured that the accuracy and integrity of the data was preserved at all stages, agreed to be accountable for all aspects of this study, was in charge of the overall direction and planning of the study, and contributed to the writing of the manuscript with input from all authors. HA and TT collected the data for the study, assessed to conduct and interpret the analysis, and wrote the manuscript. YL, ST, MA, AJ, RD, and EC revised critically the final version of the manuscript and assessed to interpret the analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This retrospective, single-center study was approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center, and informed consent for publication was obtained from all participants.

Consent for publication
This study was granted waiver for consent.

Competing interests
Dr. Amir A Jazayeri received research funding from Novartis, AstraZeneca, Bristol-Myers Squibb, Pfizer, Lilly, served on Advisory Board foriovance, Alive, Almac, and Data Safety Monitoring Board for Genetech. Dr. Ramona Dadu received research funding from Merck, Eisai, AstraZeneca, and served on Advisory Board for Bristol-Myers Squibb. The other authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Departments of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Departments of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Departments of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Received: 16 October 2018 Accepted: 9 January 2019
Published online: 06 February 2019

References
1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Nivolumab after Chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.
2. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
3. Kaufman Howard I, Russell Jeffery, Hamid Omid, Bhatia Shailender, Terheyden Patrick, D’Angelo Sandra P., et al. Nivolumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016. 17(10): p. 1374–1385.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(11):23–34.
5. Massard C, Gordon MS, Sharma S, Raffi S, Wainberg ZA, Luke J, et al. Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder Cancer. J Clin Oncol. 2016;34(26):3119–25.
6. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.
7. Rosenberg Jonathan E, Jean H-C, Tom P, van der Heijden Michiel S, Balar Arjun V, Andrea N, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.
8. Seiwert Tanguy V, Barbara B, Ranee M, Jared W, Raanan B, Paul EJ, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65.
9. Anas Y, Armando S, Margaret S, Luigi JP, Timmerman John M, Stephen A, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–94.
10. Andrews A. Treating with checkpoint inhibitors-figure $1 million per patient. Am Health Drug Benefits. 2015;8(Spec Issue)9.
11. Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. Bmj. 2018;352.
12. Stephen HF, Jason C, Pavlick Anna C, Caroline R, Grossmann Kenneth F, McDermott David F, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–68.
13. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.
14. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.
15. Abu-Sheh H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6:95.
16. Abu-Sheh Hamzah, Tang Tenglong, Ali Faisal, Johnson Daniel, Qiao Wei, Diab Adi, et al. Haensen Joeg CF, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):119–42.
17. Wang Y, Abu-Sheh H, Mao E, Ali N, Ali FS, Qiao W, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6(1):37.
18. Wang Y, Abu-Sheh H, Mao E, Ali N, Qiao W, Trinh VA, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24(8):1695–705.
19. Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report. Lung Cancer. 2016;99:148–50.
20. Michot JM, Ragou P, Carbonnel F, Champiat S, Vosin AL, Mateus C, et al. Significance of immune-related lipase increase induced by Antiprogrammed Death-1 or death Ligand-1 antibodies: a brief communication. J Immunother. 2018;41:84–5.
21. Su Q, Zhang XC, Zhang CG, Hou YL, Yao YX, Cao BW. Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis. J Immunol Res. 2018;2018:1027532.
22. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Liguèr S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–209.
23. Hellmann MD, Rzvi NA, Goldman JW, Gettinner SN, Borgiae H, Brahamer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-
small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.

25. Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with Nivolumab + Ipilimumab. J Natl Cancer Inst. 2017;109(4).

26. Brahmer JR, Christina L, Schneider Bryan J, Atkins Michael B, Brassil Kelly J, Caterino Jeffrey M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–68.

27. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.

28. Thompson JA. New NCCN guidelines: recognition and Management of ImmunoTherapy-Related Toxicity. J Natl Compr Cancer Netw. 2018;16(5s):594–6.

29. Edge SB, Compton CC. The American joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.

30. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and Unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–94.

31. Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R, Clinical assessment of immune-related adverse events. Ther Adv Med Oncol. 2018;10: p. 1758835918764628.

32. Ismail OZ, Bhayana V. Lipase or amylase for the diagnosis of acute pancreatitis? Clin Biochem. 2017;50(18):1275–80.

33. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;Jco2017776385.

34. Dupuis Carolyn S, Veronica B, Giles W, Karam Adib R, Anupam S, Wahid W, et al. Diagnosis and management of acute pancreatitis and its complications. Gastrointest Interv. 2013;2(1):36–46.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions